Kamada Ltd. logo
Kamada Ltd. KMDA
$ 7.58 4.41%
report update icon

Quarterly report 2025-Q4
added 05-06-2026

Kamada Ltd. Income Statement 2025-2011 | KMDA

Brief overview of income trends at Kamada Ltd.

The comparison covers a five-year financial horizon. Revenue reported by Kamada Ltd. was $133 million at the beginning of the period and $180 million at the end. Across the full period, sales moved by +35.4%; the average annual rate was 6.3%. The direction is positive, but the growth rate is not particularly high.

At the gross-profit level, the result moved from 47.6 million dollars to 76.4 million dollars, a change of +60.7%. The cost base moved more slowly than the top line, which supported margins. At the margin level, the figure shifted from 35.7% to 42.3%. The margin shift points to a more favorable sales-and-cost structure.

EBITDA was 19.2 million dollars at the beginning and 26.2 million dollars at the end of the period (+36.4%). Operating performance was consistent with the change in sales. Comparing the endpoints gives EBITDA margins of 14.4% and 14.5%. Operating profitability remained broadly stable.

Over the period, net income shifted from 17.1 million dollars to 20.2 million dollars (+17.8%). Net income reached a five-year high at the end of the interval.

Market value was $284 million at the start and $490 million at the end. Market value supported the favorable financial trajectory.

Summary assessment

The indicators form a favorable picture of business development. The positive side is supported by a steady EBITDA margin, a larger revenue base and better sales economics. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Kamada Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

490 M 413 M 298 M 260 M 271 M 284 M 264 M 212 M 207 M 222 M 134 M 145 M 495 M - -

Shares

57.6 M 57.5 M 48.8 M 44.8 M 44.8 M 43.9 M 40.6 M 40.4 M 38 M 36.4 M 36.2 M 36 M 33.4 M - -

Historical Prices

8.5 7.18 6.1 5.81 6.05 6.47 6.5 5.25 5.45 6.24 3.7 4.03 15.1 - -

Net Income

20.2 M 14.5 M 8.28 M -2.32 M -2.23 M 17.1 M 22.3 M 22.3 M 6.9 M -6.73 M -11.3 M -13.2 M 400 K 260 K -3.49 M

Revenue

180 M 161 M 143 M 129 M 104 M 133 M 127 M 114 M 103 M 77.5 M 69.9 M 71.1 M 70.6 M 72.7 M 55.9 M

Cost of Revenue

104 M 91 M 87 M 82.6 M 73.3 M 85.7 M 77.4 M 73 M 70.7 M 56.1 M 54.5 M - - - -

Gross Profit

76.4 M 70 M 55.5 M 46.7 M 30.3 M 47.6 M 49.7 M 41.5 M 32.1 M 21.4 M 15.8 M 15 M 26.4 M 22.7 M 15.7 M

Operating Income

26.2 M 20.1 M 10.1 M 4.53 M -696 K 19.2 M 22.8 M 19.3 M 7.44 M -5.48 M -11.4 M - - - -

EBITDA

26.2 M 20.1 M 10.1 M 4.53 M -696 K 19.2 M 22.8 M 19.3 M 7.44 M -1.98 M -8.2 M -8.71 M 6.7 M 4.61 M 541 K

Operating Expenses

- - - - - 69 K 14 K 22.2 M 24.6 M 27.1 M 27.2 M 26.6 M 22.2 M 18.5 M 18 M

General and Administrative Expenses

18.7 M 15.7 M 14.4 M 12.8 M 12.6 M 9.36 M 9.22 M 7.84 M 7.62 M 6.64 M 6.52 M 7.1 M 9.5 M 4.41 M 4.82 M

All numbers in USD currency

Quarterly Income Statement Kamada Ltd.

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

57.6 M - - - 57.5 M - - - 48.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

20.2 M 5.3 M 7.38 M 3.96 M 14.5 M 3.86 M 4.43 M 2.36 K 8.28 M 3.22 K 1.81 M -1.81 M - - - - - -845 K - - - 6.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

180 M 47 M 44.8 M 44 M 161 M 41.7 M 42.5 M 37.7 K 143 M 37.9 K 37.4 M 30.7 M - - - - - 23 M - - - 35.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

104 M 27.2 M 25.8 M 23.3 M 91 M 24.5 M 23.5 M 21 K 87 M 23.1 K 23 M 18.9 M - - - - - 17.3 M - - - 20.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

76.4 M 19.8 M 18.9 M 20.7 M 70 M 17.2 M 19 M 16.8 K 55.5 M 14.8 K 14.4 M 11.8 M - - - - - 5.73 M - - - 14.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

26.2 M 7.82 M 7.07 M 7.8 M 20.1 M 5.29 M 5.64 M 4.04 K 10.1 M 4.37 K 2.63 M 289 K - - - - - -804 K - - - 7.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

26.2 M 7.82 M 7.07 M 7.8 M 20.1 M 5.29 M 5.64 M 4.04 K 10.1 M 4.37 K 2.63 M 289 K - - - - - -804 K - - - 7.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

18.7 M 4.82 M 4.07 M 4.2 M 15.7 M 4.01 M 3.78 M 3.79 K 14.4 M 3.7 K 3.48 M 3.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Kamada Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada